Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONP-002 in adults with mild traumatic brain injury
NCT06870240Phase 2Not yet recruiting
- Sponsor
- Oragenics, Inc.
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Nanoparticles, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of ONP-002 in traumatic brain injury (TBI), sponsored by Oragenics, Inc.. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
ONP-002
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT06870240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06870240.